Sort
10,766 grants matching “checkpoint inhibitor”
Nutrient Regulation of Cancer Cell Growth
$649,928Heather Christofk · University Of California Los Angeles · R01 · FY2025 · CA
Targeting DHX9 to trigger viral mimicry and immunotherapy responsiveness in Small Cell Lung Cancer (SCLC)
$649,679Israel Canadas · Research Inst Of Fox Chase Can Ctr · R37 · FY2024 · CA
Targeting DHX9 to trigger viral mimicry and immunotherapy responsiveness in Small Cell Lung Cancer (SCLC)
$649,679Israel Canadas · Research Inst Of Fox Chase Can Ctr · R37 · FY2025 · CA
A Registry-Based Study of Patterns of Use of Targeted Therapies for Metastatic Cancers in Diverse Populations
$649,510Christine Veenstra · University Of Michigan At Ann Arbor · R37 · FY2022 · CA
Atherosclerosis, Prostaglandin Inhibition and Checkpoint Blockade
$649,492Garret A Fitzgerald · University Of Pennsylvania · R01 · FY2020 · HL
Inhibition of regeneration restraining pathways to promote healing
$649,391Luis Andres Garza · Johns Hopkins University · R01 · FY2025 · AR
Functional Analysis of MicroRNAs and Target Genes in Immune Tolerance
$649,382David Nemazee · Scripps Research Institute, The · R01 · FY2024 · AI
Functional Analysis of MicroRNAs and Target Genes in Immune Tolerance
$649,382David Nemazee · Scripps Research Institute, The · R01 · FY2023 · AI
Imaging Acidosis and Immune Therapy in PDAC
$649,329Shari Pilon-Thomas · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2024 · CA
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer
$649,094Cesar M Castro · Massachusetts General Hospital · R01 · FY2022 · CA
Improving emergency care and outcomes of immune-related adverse events: The immune-related emergency disposition index (IrEDi)
$648,983Cielito C Reyes-Gibby · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Anti-tumor and autoimmunity signatures in Down syndrome
$648,776Jane Hoyt Buckner · Benaroya Research Inst At Virginia Mason · R01 · FY2023 · CA
Targeting tumoral Lactobacillus iners to improve outcomes in cervical cancers
$648,677Lauren Elizabeth Colbert · University Of Tx Md Anderson Can Ctr · R37 · FY2025 · CA
Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122
$648,555David A. Hafler · Yale University · R01 · FY2024 · CA
Signal and Transcription Factor Network interactions in Head and Neck Cancer
$648,446Carter Van Waes · National Institute On Deafness And Other Communication Disorders · ZIA · FY2020 · DC
Targeting polo-like kinase 1 (PLK1) for treatment of small cell lung cancer
$648,269Taofeek K Owonikoko · University Of Maryland Baltimore · R01 · FY2025 · CA
Immunological consequences of LINE-1 expression in cancer
$648,232Katherine B Chiappinelli · George Washington University · R01 · FY2024 · CA
PI3K Pathway Mutations in Head and Neck Cancer
$648,229Jennifer R Grandis · University Of California, San Francisco · R01 · FY2019 · DE
HIFU-immunotherapy in pancreatic cancer
$648,066Katherine W Ferrara · Stanford University · R01 · FY2020 · CA
High-flow microfluidics of leukapheresis blood products for functional analysis of breast circulating tumor cells
$647,628Mehmet Toner · Massachusetts General Hospital · R01 · FY2025 · CA
Pathological B Cells: Novel Strategies to Prevent and Treat Chronic GVHD
$647,349Stefanie Sarantopoulos · Duke University · R01 · FY2015 · HL
Modulating the PD-1/PD-L1 checkpoint to promote antitumor activity of HER2 CAR T cells in patients with sarcoma
$647,322Meenakshi G Hegde · Baylor College Of Medicine · R01 · FY2025 · CA
Bladder cancer PD-L1 control of homologous recombination: Basic mechanisms applied to novel treatments
$646,659Tyler J. Curiel · Dartmouth-Hitchcock Clinic · R01 · FY2022 · CA
Novel regulatory mechanisms and agonists of STING
$646,571Xuewu Zhang · Ut Southwestern Medical Center · R01 · FY2024 · CA
Selective disruption of histone deacetylase complexes using protein interaction modulators
$646,119Marc Vidal · Dana-Farber Cancer Inst · R01 · FY2024 · CA